Logo image of SCYX

SCYNEXIS INC (SCYX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SCYX - US8112922005 - Common Stock

0.627 USD
0 (-0.56%)
Last: 12/19/2025, 8:15:31 PM
0.628 USD
+0 (+0.16%)
After Hours: 12/19/2025, 8:15:31 PM
Fundamental Rating

3

SCYX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. SCYX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, SCYX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCYX had negative earnings in the past year.
In the past year SCYX has reported a negative cash flow from operations.
SCYX had negative earnings in 4 of the past 5 years.
In the past 5 years SCYX reported 4 times negative operating cash flow.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

The Return On Assets of SCYX (-49.54%) is worse than 61.78% of its industry peers.
Looking at the Return On Equity, with a value of -69.45%, SCYX is in line with its industry, outperforming 45.03% of the companies in the same industry.
Industry RankSector Rank
ROA -49.54%
ROE -69.45%
ROIC N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Gross Margin of SCYX (127.76%) is better than 98.43% of its industry peers.
SCYX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SCYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 127.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCYX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SCYX has been increased compared to 5 years ago.
Compared to 1 year ago, SCYX has a worse debt to assets ratio.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.04, we must say that SCYX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.04, SCYX is not doing good in the industry: 75.92% of the companies in the same industry are doing better.
SCYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.04
ROIC/WACCN/A
WACC9.34%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 5.75 indicates that SCYX has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.75, SCYX is doing good in the industry, outperforming 67.02% of the companies in the same industry.
SCYX has a Quick Ratio of 5.75. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
SCYX's Quick ratio of 5.75 is fine compared to the rest of the industry. SCYX outperforms 68.06% of its industry peers.
Industry RankSector Rank
Current Ratio 5.75
Quick Ratio 5.75
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

SCYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.08%, which is quite impressive.
Looking at the last year, SCYX shows a very negative growth in Revenue. The Revenue has decreased by -65.77% in the last year.
SCYX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 99.01% yearly.
EPS 1Y (TTM)31.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
Revenue 1Y (TTM)-65.77%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%-49.39%

3.2 Future

The Earnings Per Share is expected to grow by 3.11% on average over the next years.
Based on estimates for the next years, SCYX will show a small growth in Revenue. The Revenue will grow by 1.60% on average per year.
EPS Next Y13.07%
EPS Next 2Y36.7%
EPS Next 3Y-0.41%
EPS Next 5Y3.11%
Revenue Next Year-24.13%
Revenue Next 2Y72.19%
Revenue Next 3Y-39.59%
Revenue Next 5Y1.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCYX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.7%
EPS Next 3Y-0.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCYX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SCYNEXIS INC

NASDAQ:SCYX (12/19/2025, 8:15:31 PM)

After market: 0.628 +0 (+0.16%)

0.627

0 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-10 2026-03-10/amc
Inst Owners28.09%
Inst Owner Change5.88%
Ins Owners2.16%
Ins Owner Change3.02%
Market Cap26.32M
Revenue(TTM)2.93M
Net Income(TTM)-25.30M
Analysts84.44
Price Target3.74 (496.49%)
Short Float %2.82%
Short Ratio2.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.21%
Min EPS beat(2)16.67%
Max EPS beat(2)27.76%
EPS beat(4)4
Avg EPS beat(4)35.67%
Min EPS beat(4)16.67%
Max EPS beat(4)59.89%
EPS beat(8)6
Avg EPS beat(8)16.42%
EPS beat(12)9
Avg EPS beat(12)10.62%
EPS beat(16)11
Avg EPS beat(16)12.39%
Revenue beat(2)2
Avg Revenue beat(2)445.05%
Min Revenue beat(2)121.75%
Max Revenue beat(2)768.35%
Revenue beat(4)3
Avg Revenue beat(4)205.53%
Min Revenue beat(4)-90.6%
Max Revenue beat(4)768.35%
Revenue beat(8)6
Avg Revenue beat(8)194.61%
Revenue beat(12)9
Avg Revenue beat(12)128.92%
Revenue beat(16)9
Avg Revenue beat(16)88.28%
PT rev (1m)0%
PT rev (3m)-21.43%
EPS NQ rev (1m)18.75%
EPS NQ rev (3m)2.71%
EPS NY rev (1m)5.06%
EPS NY rev (3m)-41.51%
Revenue NQ rev (1m)-47.52%
Revenue NQ rev (3m)-48.58%
Revenue NY rev (1m)-42.84%
Revenue NY rev (3m)-48.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.98
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.07
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.54%
ROE -69.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 127.76%
FCFM N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.75
Quick Ratio 5.75
Altman-Z -11.04
F-Score3
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
EPS Next Y13.07%
EPS Next 2Y36.7%
EPS Next 3Y-0.41%
EPS Next 5Y3.11%
Revenue 1Y (TTM)-65.77%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%-49.39%
Revenue Next Year-24.13%
Revenue Next 2Y72.19%
Revenue Next 3Y-39.59%
Revenue Next 5Y1.6%
EBIT growth 1Y33.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-174.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-174.5%
OCF growth 3YN/A
OCF growth 5YN/A

SCYNEXIS INC / SCYX FAQ

Can you provide the ChartMill fundamental rating for SCYNEXIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SCYX.


What is the valuation status of SCYNEXIS INC (SCYX) stock?

ChartMill assigns a valuation rating of 0 / 10 to SCYNEXIS INC (SCYX). This can be considered as Overvalued.


What is the profitability of SCYX stock?

SCYNEXIS INC (SCYX) has a profitability rating of 1 / 10.


What is the financial health of SCYNEXIS INC (SCYX) stock?

The financial health rating of SCYNEXIS INC (SCYX) is 6 / 10.